Activation of the sympathetic nervous system (SNS) drives breast cancer progression in preclinical breast cancer models, but it has yet to be established if neoplastic and stromal cells residing in the tumor are directly targeted by locally released norepinephrine (NE). In murine orthotopic and spontaneous mammary tumors, tyrosine hydroxylase (TH)+ sympathetic nerves were limited to the periphery of the tumor. No TH+ staining was detected deeper within these tumors, even in regions with a high density of blood vessels. NE concentration was much lower in tumors compared to the more densely innervated spleen, reflecting the relative paucity of tumor TH+ innervation. Tumor and spleen NE concentration decreased with increased tissue mass. In mice treated with the neurotoxin 6-hydroxydopamine (6-OHDA) to selectively destroy sympathetic nerves, tumor NE concentration was reduced approximately 50%, suggesting that the majority of tumor NE is derived from local sympathetic nerves. To evaluate NE utilization, NE turnover in orthotopic 4T1 mammary tumors was compared to spleen under baseline and stress conditions. In non-stressed mice, NE turnover was equivalent between tumor and spleen. In mice exposed to a stressor, tumor NE turnover was increased compared to spleen NE turnover, and compared to nonstressed tumor NE turnover. Together, these results demonstrate that NE in mammary tumors is derived from local sympathetic nerves that synthesize and metabolize NE. However, differences between spleen and tumor NE turnover with stressor exposure suggest that sympathetic NE release is regulated differently within the tumor microenvironment compared to the spleen. Local mammary tumor sympathetic innervation, despite its limited distribution, is responsive to stressor exposure and therefore can contribute to stress-induced tumor progression.
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Introduction
Activation of the sympathetic nervous system (SNS), release of norepinephrine (NE), and adrenergic receptor (AR) signaling regulates solid tumor growth and metastasis (reviewed in (Cole et al., 2015) ). AR-expressing cells reside within tumors and within extra-tumoral organs that receive abundant sympathetic innervation, such as spleen and bone marrow (Campbell et al., 2012; Katayama et al., 2006; Mendez-Ferrer et al., 2008) . In ovarian and pancreatic tumors, psychosocial stressors and environmental conditions that activate the SNS elevate tumor NE concentration (Eng et al., 2015; Lutgendorf et al., 2011; Thaker et al., 2006) . In prostate cancer, the density of tumor sympathetic nerves correlates with poor clinical outcomes (Magnon et al., 2013) . These reports provide evidence for local release of NE within the microenvironment of solid tumors, but in breast cancer, local sympathetic innervation and release of NE have yet to be evaluated.
Several experimental approaches have been used to characterize sympathetic innervation and NE release in peripheral tissues. Immunohistochemical detection of tyrosine hydroxylase (TH), the rate-limiting enzyme in catecholamine synthesis, provides insight into the abundance and anatomical location of sympathetic nerves (Felten and Olschowka, 1987; Lorton et al., 2009 ). The neurotoxin 6-hydroxydopamine (6-OHDA) selectively ablates sympathetic nerves and markedly depletes NE in innervated organs (Lorton http://dx.doi.org/10.1016/j.bbi.2015.12.014 0889-1591/Ó 2015 Elsevier Inc. All rights reserved.
